Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
Gustin, D.J., Ma, Z., Min, X., Li, Y., Hedberg, C., Guimaraes, C., Porter, A.C., Lindstrom, M., Lester-Zeiner, D., Xu, G., Carlson, T.J., Xiao, S., Meleza, C., Connors, R., Wang, Z., Kayser, F.(2011) Bioorg Med Chem Lett 21: 2492-2496
- PubMed: 21392988 
- DOI: https://doi.org/10.1016/j.bmcl.2011.02.052
- Primary Citation of Related Structures:  
3QK5 - PubMed Abstract: 
Starting from a series of ureas that were determined to be mechanism-based inhibitors of FAAH, several spirocyclic ureas and lactams were designed and synthesized. These efforts identified a series of novel, noncovalent FAAH inhibitors with in vitro potency comparable to known covalent FAAH inhibitors. The mechanism of action for these compounds was determined through a combination of SAR and co-crystallography with rat FAAH.
Organizational Affiliation: 
Department of Chemistry, Amgen Inc., South San Francisco, 1120 Veterans Blvd., South San Francisco, CA 94080, USA. dgustin@amgen.com